NDAQ Nasdaq Inc.

Nasdaq Halts SCWorx Corp.

Nasdaq Halts SCWorx Corp.

NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in SCWorx Corp. (Nasdaq: WORX) was changed to "additional information requested" from the company. Trading in the company’s stock had been halted on April 22, 2020 at 9:25:05 Eastern Time  at a last sale price of $5.755.

Trading will remain halted until SCWorx Corp. has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at .

NDAQO

Nasdaq Media Contact:

Bianca Fata

EN
06/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nasdaq Inc.

 PRESS RELEASE

Nasdaq Raises Medium‑Term Revenue Outlook and Outlines Strategy for It...

Nasdaq Raises Medium‑Term Revenue Outlook and Outlines Strategy for Its Next Phase of Scalable Growth at 2026 Investor Day Nasdaq raises medium-term Solutions revenue outlook to 9-12% growthMaintains medium-term outlook for expense growth of 5-8%Company reinforces its position as trusted transformation partner in the AI eraCommits to actioning AI productivity program with an expense efficiency target of $100 million by 2027 NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today will host its Investor Day at 8:00 a.m. ET, where Adena Friedman, Nasdaq Chair and CEO, Sarah ...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nasdaq, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 February 2026 in which we reassessed the appropriateness of the ratings in the context of t...

 PRESS RELEASE

Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq ...

Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date January 30, 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- At the end of the settlement date of January 30, 2026, short interest in 3,547 Nasdaq Global MarketSM securities totaled 15,574,683,465 shares compared with 15,349,969,813 shares in 3,515 Global Market issues reported for the prior settlement date of January 15, 2026. The January short interest represents 2.58 days compared with 2.88 days for the prior reporting period. Short interest in 1,666 securities on The Nasdaq Capital Mark...

 PRESS RELEASE

Nasdaq Launches new Private Capital Indexes, expanding Its Private Cap...

Nasdaq Launches new Private Capital Indexes, expanding Its Private Capital Solutions Platform By enhancing Nasdaq Private Capital Solutions, the platform reinforces its capacity to deliver high‑quality benchmarking, robust data, and advanced analytics for today’s increasingly complex private markets. The new benchmark suite extends this capability with broader market representation and workflow‑ready insights across private capital strategies. NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the launch of the Nasdaq Private Capital™ Indexes, a new suite o...

 PRESS RELEASE

Nasdaq 2026 Investor Day

Nasdaq 2026 Investor Day NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nasdaq will hold its 2026 Investor Day at the company’s Global Headquarters in Times Square, New York. Due to limited capacity, in-person attendance is by invitation only. When: Wednesday, February 25, 2026  8:00 AM – 12:30 PM ETWhere:Webcast registration link:    The agenda, slide presentation and a live webcast will be available on the day of the event on Nasdaq’s IR website: . A replay will be available after the conclusion of the event. About NasdaqNasdaq (Nasdaq: NDAQ) is a leading technology platform that powers t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch